Lonza 1H Revenues: CHF 1.7 billion (-11%) 1H Earnings: CHF 41.0 million (-105%) Comments: Pharma and Biotech sales were down 15% to 609 million Swiss francs (CHF). The company expects to reduce CHF 100 million in costs by 2016 by restructuring its global manufacturing operations. The Swords facility was closed in the second quarter. The company is consolidating its Microbial Biologics assets and activities to its Visp site in Switzerland and will close its plant in Hopkinton, MA. The company ...